Skip to main content

Table 2 Demographic and baseline characteristics of patients

From: Real-life effectiveness of budesonide/formoterol maintenance and reliever therapy in asthma patients across Asia: SMARTASIA study

Demographic characteristic

 

Number (%) of patients N = 862

Sex

Male

407 (47.2)

 

Female

455 (52.8)

Age (years)

n

862

 

Mean (SD)

44.7 (13.7)

 

Range

18 - 81

Race

Asian

862 (100.0)

BMI (kg/m**2)

n

862

 

Mean (SD)

24.36 (4.10)

 

Range

14.2 - 47.5

Time since diagnosis (years)

n

862

 

Mean (SD)

10.73 (12.03)

 

Range

0.1 - 60.0

Smoking

Non smoker

744 (86.3)

 

Ex-smoker

84 (9.7)

 

Occasional smoker

18 (2.1)

 

Habitual smoker

16 (1.9)

Pack-years

n

116

 

Mean (SD)

4.8 (2.9)

 

Range

0 - 15

Inhaled GCS at entry

No

143 (16.6)

 

Yes

719 (83.4)

Inhaled GCS at entry: dose (ug/day)

n

317

 

Mean (SD)

557.8 (321.5)

 

Range

50 - 1600

FEV1 (L)

n

862

 

Mean (SD)

2.063 (0.709)

 

Range

0.69 - 4.63

FEV1% of predicted normal *

n

862

 

Mean (SD)

70.38 (17.37)

 

Range

22.4 - 124.3

FEV1% Reversibility

n

862

 

Mean (SD)

26.50 (15.15)

 

Range

9.8 - 139.5

  1. a FAS: All enrolled subjects except for screening failure.
  2. * Predicted normal FEV1 value (post-bronchodilator) was calculated according to ERS [22].